- $58.35bn
- $57.34bn
- $2.31bn
Brief: Alliance Foundation Trials And Natera Announce Aft-70 Navigate A Global, Randomized, Phase Iii Trial Evaluating Genentech’S Oral Selective Estrogen Receptor Degrader With Signatera Mrd-Guided Cdk4/6 Inhibitor Therapy In Breast Cancer
US RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddy
Brief: Natera Says Signatera Commercial Launch In Japan Expected In 1H 2027
Brief: Natera To Support New Clinical Trial Assessing Ctdna Dynamics With Latitud In Advanced Skin Cancers
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage
Natera, Inc. reports results for the quarter ended June 30 - Earnings Summary
Natera Q2 revenue rises beats estimates on higher overall test volumes, raises 2026 outlook
Brief: Natera Q2 EPS USD -0.47
U.S. STOCKS ON THE MOVE-Natera, nLIGHT, Micron
U.S. STOCKS ON THE MOVE-Natera, nLIGHT, Forte Biosciences
Natera rises after EU certification for cancer test
U.S. RESEARCH ROUNDUP-Applied Materials, CME Group, Nasdaq
U.S. STOCKS ON THE MOVE-Regenxbio, Repay, Natera, Fortune Brands
U.S. STOCKS ON THE MOVE-Regenxbio, Repay, Natera, Fortune Brands
Natera rises as partners on late-stage cancer trial
Natera, Aveta partner on late-stage head and neck cancer trial (updated)
Natera, Aveta partner on late-stage head and neck cancer trial
Brief: Natera And Eledon Announce Strategic Partnership For Prospera™ Monitoring In Planned Phase 3 Kidney Transplant Trial
Street View: Japan nod for Natera's cancer test meaningful, but payoff seen later